These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 37732203)
1. Structural mechanisms for VMAT2 inhibition by tetrabenazine. Dalton MP; Cheng MH; Bahar I; Coleman JA bioRxiv; 2024 Feb; ():. PubMed ID: 37732203 [TBL] [Abstract][Full Text] [Related]
2. Structural mechanisms for VMAT2 inhibition by tetrabenazine. Dalton MP; Cheng MH; Bahar I; Coleman JA Elife; 2024 Mar; 12():. PubMed ID: 38517752 [TBL] [Abstract][Full Text] [Related]
3. Transport and inhibition mechanism for VMAT2-mediated synaptic vesicle loading of monoamines. Wang Y; Zhang P; Chao Y; Zhu Z; Yang C; Zhou Z; Li Y; Long Y; Liu Y; Li D; Wang S; Qu Q Cell Res; 2024 Jan; 34(1):47-57. PubMed ID: 38163846 [TBL] [Abstract][Full Text] [Related]
4. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine. Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308 [TBL] [Abstract][Full Text] [Related]
5. Transport and inhibition mechanisms of human VMAT2. Wu D; Chen Q; Yu Z; Huang B; Zhao J; Wang Y; Su J; Zhou F; Yan R; Li N; Zhao Y; Jiang D Nature; 2024 Feb; 626(7998):427-434. PubMed ID: 38081299 [TBL] [Abstract][Full Text] [Related]
6. A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport. Bernstein AI; Stout KA; Miller GW J Neurosci Methods; 2012 Aug; 209(2):357-66. PubMed ID: 22698664 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of neurotransmitter transport and drug inhibition in human VMAT2. Pidathala S; Liao S; Dai Y; Li X; Long C; Chang CL; Zhang Z; Lee CH Nature; 2023 Nov; 623(7989):1086-1092. PubMed ID: 37914936 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone. Støve SI; Skjevik ÅA; Teigen K; Martinez A Commun Biol; 2022 Nov; 5(1):1283. PubMed ID: 36418492 [TBL] [Abstract][Full Text] [Related]
9. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis. Yaffe D; Vergara-Jaque A; Forrest LR; Schuldiner S Proc Natl Acad Sci U S A; 2016 Nov; 113(47):E7390-E7398. PubMed ID: 27821772 [TBL] [Abstract][Full Text] [Related]
10. Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry. Wimalasena K Med Res Rev; 2011 Jul; 31(4):483-519. PubMed ID: 20135628 [TBL] [Abstract][Full Text] [Related]
11. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Yao Z; Wei X; Wu X; Katz JL; Kopajtic T; Greig NH; Sun H Eur J Med Chem; 2011 May; 46(5):1841-8. PubMed ID: 21396745 [TBL] [Abstract][Full Text] [Related]
12. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. Finn JP; Edwards RH J Biol Chem; 1997 Jun; 272(26):16301-7. PubMed ID: 9195934 [TBL] [Abstract][Full Text] [Related]
13. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders. Koch J; Shi WX; Dashtipour K Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050 [TBL] [Abstract][Full Text] [Related]
20. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Erickson JD; Schafer MK; Bonner TI; Eiden LE; Weihe E Proc Natl Acad Sci U S A; 1996 May; 93(10):5166-71. PubMed ID: 8643547 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]